207 related articles for article (PubMed ID: 18053727)
1. Novel anti-HIV cyclotriazadisulfonamide derivatives as modeled by ligand- and receptor-based approaches.
Pinheiro JR; Bitencourt M; da Cunha EF; Ramalho TC; Freitas MP
Bioorg Med Chem; 2008 Feb; 16(4):1683-90. PubMed ID: 18053727
[TBL] [Abstract][Full Text] [Related]
2. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
3. 3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors.
Durdagi S; Mavromoustakos T; Papadopoulos MG
Bioorg Med Chem Lett; 2008 Dec; 18(23):6283-9. PubMed ID: 18951793
[TBL] [Abstract][Full Text] [Related]
4. Design and cellular kinetics of dansyl-labeled CADA derivatives with anti-HIV and CD4 receptor down-modulating activity.
Vermeire K; Lisco A; Grivel JC; Scarbrough E; Dey K; Duffy N; Margolis L; Bell TW; Schols D
Biochem Pharmacol; 2007 Aug; 74(4):566-78. PubMed ID: 17603023
[TBL] [Abstract][Full Text] [Related]
5. Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors.
Teixeira C; Serradji N; Maurel F; Barbault F
Eur J Med Chem; 2009 Sep; 44(9):3524-32. PubMed ID: 19410340
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and structure-activity relationship studies of CD4 down-modulating cyclotriazadisulfonamide (CADA) analogues.
Bell TW; Anugu S; Bailey P; Catalano VJ; Dey K; Drew MG; Duffy NH; Jin Q; Samala MF; Sodoma A; Welch WH; Schols D; Vermeire K
J Med Chem; 2006 Feb; 49(4):1291-312. PubMed ID: 16480266
[TBL] [Abstract][Full Text] [Related]
7. Modelling of cytotoxicity data (CC50) of anti-HIV 1-[5-chlorophenyl) sulfonyl]-1H-pyrrole derivatives using calculated molecular descriptors and Levenberg-Marquardt artificial neural network.
Arab Chamjangali M
Chem Biol Drug Des; 2009 Apr; 73(4):456-65. PubMed ID: 19291106
[TBL] [Abstract][Full Text] [Related]
8. MIA-QSAR modelling of anti-HIV-1 activities of some 2-amino-6-arylsulfonylbenzonitriles and their thio and sulfinyl congeners.
Freitas MP
Org Biomol Chem; 2006 Mar; 4(6):1154-9. PubMed ID: 16525561
[TBL] [Abstract][Full Text] [Related]
9. Probabilistic neural network model for the in silico evaluation of anti-HIV activity and mechanism of action.
Vilar S; Santana L; Uriarte E
J Med Chem; 2006 Feb; 49(3):1118-24. PubMed ID: 16451076
[TBL] [Abstract][Full Text] [Related]
10. 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.
San Juan AA
Bioorg Med Chem Lett; 2008 Feb; 18(3):1181-94. PubMed ID: 18155520
[TBL] [Abstract][Full Text] [Related]
11. Neural networks: Accurate nonlinear QSAR model for HEPT derivatives.
Douali L; Villemin D; Cherqaoui D
J Chem Inf Comput Sci; 2003; 43(4):1200-7. PubMed ID: 12870912
[TBL] [Abstract][Full Text] [Related]
12. Biological profiling of anti-HIV agents and insight into CCR5 antagonist binding using in silico techniques.
Carrieri A; Pérez-Nueno VI; Fano A; Pistone C; Ritchie DW; Teixidó J
ChemMedChem; 2009 Jul; 4(7):1153-63. PubMed ID: 19544518
[TBL] [Abstract][Full Text] [Related]
13. A neural networks-based drug discovery approach and its application for designing aldose reductase inhibitors.
Hu L; Chen G; Chau RM
J Mol Graph Model; 2006 Jan; 24(4):244-53. PubMed ID: 16226911
[TBL] [Abstract][Full Text] [Related]
14. In silico studies toward the discovery of new anti-HIV nucleoside compounds through the use of TOPS-MODE and 2D/3D connectivity indices. 2. Purine derivatives.
Vilar S; Estrada E; Uriarte E; Santana L; Gutierrez Y
J Chem Inf Model; 2005; 45(2):502-14. PubMed ID: 15807516
[TBL] [Abstract][Full Text] [Related]
15. Predicting anti-HIV activity of PETT derivatives: CoMFA approach.
Ravichandran V; Agrawal RK
Bioorg Med Chem Lett; 2007 Apr; 17(8):2197-202. PubMed ID: 17307357
[TBL] [Abstract][Full Text] [Related]
16. Structure-based QSAR analysis of a set of 4-hydroxy-5,6-dihydropyrones as inhibitors of HIV-1 protease: an application of the receptor-dependent (RD) 4D-QSAR formalism.
Santos-Filho OA; Hopfinger AJ
J Chem Inf Model; 2006; 46(1):345-54. PubMed ID: 16426069
[TBL] [Abstract][Full Text] [Related]
17. 3D-QSAR design of novel antiepileptic sulfamides.
Gavernet L; Dominguez Cabrera MJ; Bruno-Blanch LE; Estiú GL
Bioorg Med Chem; 2007 Feb; 15(3):1556-67. PubMed ID: 17158052
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ligand-based and structure-based 3D-QSAR approaches: a case study on (aryl-)bridged 2-aminobenzonitriles inhibiting HIV-1 reverse transcriptase.
Sciabola S; Carosati E; Baroni M; Mannhold R
J Med Chem; 2005 Jun; 48(11):3756-67. PubMed ID: 15916427
[TBL] [Abstract][Full Text] [Related]
19. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
[TBL] [Abstract][Full Text] [Related]
20. Small-molecule interferon inducers. Toward the comprehension of the molecular determinants through ligand-based approaches.
Musmuca I; Simeoni S; Caroli A; Ragno R
J Chem Inf Model; 2009 Jul; 49(7):1777-86. PubMed ID: 19499914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
